Quarterly report pursuant to Section 13 or 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

3 Months Ended

Sep. 30, 2022

Schedule of the Consolidated Changes in Equity

Consolidated Changes in Equity (amounts in thousands)


	Bio-Techne Shareholders
								Accumulated
				Additional				Other
	Common Stock			Paid-in		Retained		Comprehensive		Noncontrolling
	Shares	Amount		Capital		Earnings		Income(Loss)		Interest		Total
Balances at June 30, 2022	39,160		392		653,657		1,122,921		(75,200)		(759)		1,701,011
Net earnings	-		-		-		89,555		-		179		89,734
Other comprehensive loss	-		-		-		-		(16,762)		0		(16,762)
Reclassification of cumulative translation adjustment for Eminence to non-operating income	-		-		-		-		152		(33)		119
Elimination of noncontrolling equity interest from sale of Eminence	-		-		-		-		-		613		613
Share repurchases	(55)		(1)		-		(19,561)		-		-		(19,562)
Common stock issued for exercise of options	107		1		9,422		(11,428)		-		-		(2,005)
Common stock issued for restricted stock awards	11		-		-		(6,427)		-		-		(6,427)
Cash dividends	-		-		-		(12,545)		-		-		(12,545)
Stock-based compensation expense	-		-		14,364		-		-		-		14,364
Common stock issued to employee stock purchase plan	9		-		2,517		-		-		-		2,517
Employee stock purchase plan expense	-		-		97		-		-		-		97
Balances at September 30, 2022	39,232	$	392	$	680,057	$	1,162,515	$	(91,810)	$	-	$	1,751,154


	Bio-Techne Shareholders
								Accumulated
				Additional				Other
	Common Stock			Paid-in		Retained		Comprehensive		Noncontrolling
	Shares	Amount		Capital		Earnings		Income(Loss)		Interest		Total
Balances at June 30, 2021	38,955	$	390	$	534,411	$	1,085,461	$	(57,291)	$	8,263	$	1,571,234
Net earnings							69,615				(634)		68,981
Other comprehensive income (loss)									(6,925)		(39)		(6,964)
Common stock issued for exercise of options	295		3		36,345		(13,481)						22,867
Common stock issued for restricted stock awards	20		0		0		(9,765)						(9,765)
Cash dividends							(12,493)						(12,493)
Stock-based compensation expense					11,396								11,396
Common stock issued to employee stock purchase plan	3		0		1,358								1,358
Employee stock purchase plan expense					341								341
Balances at September 30, 2021	39,273	$	393	$	583,851	$	1,119,337	$	(64,216)	$	7,590	$	1,646,955

Schedule of each component of other comprehensive income (loss)


	Unrealized
	Gains		Foreign
	(Losses) on		Currency
	Derivative		Translation
	Instruments		Adjustments		Total
Balance as of June 30, 2022	$	8,069	$	(83,269)	$	(75,200)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne		4,376		(21,457)		(17,081)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽¹⁾		319				319
Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne		—		152		152
Balance as of September 30, 2022⁽²⁾	$	12,764	$	(104,574)	$	(91,810)


	Unrealized
	Gains		Foreign
	(Losses) on		Currency
	Derivative		Translation
	Instruments		Adjustments		Total
Balance as of June 30, 2021 attributable to Bio-Techne	$	(6,193)	$	(51,098)	$	(57,291)
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne		84		(8,607)		(8,523)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽¹⁾		1,598		—		1,598
Balance as of September 30, 2021 ⁽²⁾	$	(4,511)	$	(59,705)	$	(64,216)

⁽¹⁾

Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified ($417) to interest expense and recorded a related tax benefit of $98 during the quarter ended September 30, 2022. The Company reclassified ($2,091) to interest expense and a related tax benefit of $493 during the quarter ended September 30, 2021.

⁽²⁾

The Company had a net deferred tax liability of $3,921 and a net deferred tax benefit of $1,391 included in the accumulated other comprehensive income loss as of September 30, 2022 and 2021, respectively.